Allarity Therapeutics Inc. (NASDAQ:ALLR) currently has a daily average trading volume of 3.23M but it saw 3933814 shares traded on Thursday. With a market cap of 6.93M USD, stock’s current market price of $0.34 came rising about 17.09 while comparing to the previous closing price of $0.29. In past 52 weeks, the stock remained buoying in the range of price level as high as $118.30 and as low as $0.27. In the recent trading on the day, stock has struck highest price mark of $0.3454 while lowest mark touched by it was $0.281.
25-cent Stock Takes $11T Commodities Sector Digital
One brilliantly-run technology firm has successfully partnered with some of the largest players in the industry to bring a first-of-its-kind digital solution to the global commodities supply chain sector. Best of all, this upstart technology firm is currently trading undiscovered — below 25-cents per share — so very, very few investors know about it yet! For investors… it's an early-stage opportunity in a company that's bringing the US$11T global commodities sector straight into the 21st century.
All the details are in the FREE online report you can get here.
Taking a look at 20-day trading activity of Allarity Therapeutics Inc. (ALLR) gives us an average price of $0.3698, while its current price level is -99.71% below from 52-week high level whereas it is 26.21% above from lowest level seen by the stock during that period. Simple moving average of 50 days or SMA-50 of the stock’s closing price is $1.2556 while that of 200 days or SMA-200 reads an average of $16.0500. A closer look into the stock’s movement over the week reveals that its volatility is standing at 12.60% during that period while stretching the period over a month that increases to 12.88%. It is also necessary to take a look into other indicators of a stock too, to get a better idea about its price movement. And in doing so, we find stock’s 14-day relative strength index (RSI) standing at 28.63 which implies that the stock is in oversold territory.
Allarity Therapeutics Inc. (ALLR)’s stock is currently under the radar of 1 analysts who are in consensus at a 12-month price target range of between $8.00 and $8.00 for company’s shares. The average price target assigned by the average number of analysts to a stock is a way to gauge worth of any stock in next 52 weeks. And in assigning price target to a stock, some analysts adopt a bearish approach by advocating lower-than-average price target which in this case is $8.00 while some adopt bullish approach by assigning higher-than-average price target which reads the price to top $8.00. Average price target assigned by them is $8.00 which highlights an upside potential of 95.75% for the stock over that period. And to attain the median price target of $8.00 assigned by those analysts, stock has to add about 95.75% of value to its current levels.
Data by FactSet Research shows that 1 analysts have issued their ratings for the stock. 0 of them are in opinions that stock is a Sell, while 0 are advising it as an Overweight. 0 analysts suggested the investors to Buy the stock while 1 advised them to Hold. Recommendations by all of those brokerages imply a consensus rating of Hold for the stock and that issued by Wall Street to investors is Hold.
Over the week, ALLR’s stock price is moving 8.37% up while it is -22.47% when we observe its performance for the past one month. Year-to-date it is -96.68% down and over the past year, the stock is showing a downside performance of -99.58%.
The latest quarterly earnings report issued by the company was for quarter ended 3/30/2023, when its quarterly earnings per share (EPS) of -$4.43 beat the consensus estimate of -$7.88 for the same. The company is expected to be releasing its next quarterly report in 10/10/2023, for which analysts forecasted an EPS of -$7.72 while estimate for next year EPS is -$30.58. For ALLR, analysts are forecasting an EPS-growth rate of 60.50% for current year and estimate for EPS growth in next year is 35.20%.
Currently, Allarity Therapeutics Inc.’s total number of outstanding shares is 19.14M with 0.71% of that held by the insiders while 0.07% of its common stock has been owned by the institutions. Its return on asset (ROA) is -114.40% on average.
Leave a Reply